Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)

Ads

You May Also Like

Sorrento Therapeutics Chairman/CEO update to stockholders

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Dear Sorrento ...